Key Points
- Director Gilbert Kliman sold 2,500 Glaukos shares for $632,500 at an average price of $253, reducing his stake by 6.26%; he retained 37,406 shares.
- Glaukos reported quarterly EPS of $0.47, beating the consensus estimate of a $0.10 loss, while revenue rose 58% year over year to $211 million.
- Analysts’ consensus rating is Moderate Buy, with an average price target of $216.71; the stock was reported down 10.8%.
Glaukos Corporation (NYSE:GKOS - Get Free Report) Director Gilbert Kliman sold 2,500 shares of Glaukos stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $253.00, for a total transaction of $632,500.00. Following the sale, the director owned 37,406 shares in the company, valued at $9,463,718. This represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Glaukos Stock Down 10.8%
Shares of GKOS opened at $220.03 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.57 and a quick ratio of 4.09. Glaukos Corporation has a 1-year low of $80.90 and a 1-year high of $255.18. The firm has a fifty day moving average price of $177.40 and a 200 day moving average price of $143.58.
Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.57. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The company had revenue of $211.03 million for the quarter, compared to analyst estimates of $168.04 million. During the same quarter last year, the company posted ($0.16) earnings per share. The business's quarterly revenue was up 58.0% compared to the same quarter last year. Research analysts anticipate that Glaukos Corporation will post 0.50 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on the company. JPMorgan Chase & Co. upped their target price on Glaukos from $200.00 to $240.00 and gave the company an "overweight" rating in a research report on Thursday, October 29th. UBS Group assumed coverage on Glaukos in a research report on Tuesday, July 28th. They set a "neutral" rating and a $150.00 price target on the stock. BTIG Research boosted their price objective on Glaukos from $205.00 to $234.00 and gave the company a "buy" rating in a research note on Thursday, October 29th. Wells Fargo & Company increased their price objective on Glaukos from $178.00 to $226.00 and gave the company an "overweight" rating in a report on Thursday, October 29th. Finally, Wall Street Zen raised Glaukos from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $216.71.
Get Our Latest Stock Report on Glaukos
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of GKOS. Fulcrum Asset Management LLP raised its holdings in shares of Glaukos by 91.7% in the third quarter. Fulcrum Asset Management LLP now owns 184 shares of the medical instruments supplier's stock valued at $29,000 after buying an additional 88 shares during the last quarter. Allworth Financial LP purchased a new position in shares of Glaukos during the second quarter worth about $28,000. CoreCap Advisors LLC purchased a new position in shares of Glaukos during the third quarter worth about $33,000. Fortitude Family Office LLC purchased a new position in shares of Glaukos during the third quarter worth about $36,000. Finally, Provenance Wealth Advisors LLC acquired a new position in Glaukos in the 3rd quarter valued at about $44,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.
About Glaukos
(
Get Free Report)
Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company's principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.
Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
